Abstracts Archive - Page 6 of 2616 - ACR Meeting Abstracts

Abstract Number: 011 • 2026 Pediatric Rheumatology Symposium
Lung Transplant for Pediatric Dermatomyositis Patients with Interstitial Lung Disease: A Single-Center Experience
Alison Brittain¹, Elizabeth Murray², Ivana Stojkic³, Vidya Sivaraman⁴, Katelyn Krivchenia¹, Stephen Kirkby³ and Shoghik Akoghlanian⁵, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital/The Ohio State University, Columbus, OH, ³Nationwide Children's Hospital, ⁴Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁵Nationwide Childrens Hospital, Columbus, OH
Background/Purpose: Interstitial lung disease (ILD) is a feared complication of several pediatric rheumatic diseases, particularly dermatomyositis. Lung transplant is often considered as a last resort in these patients, which can lead to delayed transplant assessment…
Abstract Number: 029 • 2026 Pediatric Rheumatology Symposium
Oral vs Subcutaneous Methotrexate at High Dose for Pediatric Anterior Uveitis
Katie Choi¹ and Melissa Lerman², ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Methotrexate (MTX) is effective and steroid-sparing for pediatric non-infectious anterior uveitis, but whether subcutaneous (SC) achieves control faster than oral (PO) remains unclear. High-dose…
Abstract Number: 027 • 2026 Pediatric Rheumatology Symposium
An Examination of Brain-age-related Deviations from Normative Neurodevelopmental Trajectory in Children with Childhood-Onset Systemic Lupus Erythematosus
Josephine Machado¹, Diana Valdes Cabrera², Helen Branson³, Adrienne Davis³, Linda Hiraki², Asha Jeyanathan⁴, Deborah Levy², Lawrence Ng⁵, Birgit-Ertl Wagner³ and Andrea Knight⁶, ¹University of Toronto, Woodbridge, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, ⁴Hospital for Sick Children, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada, ⁶Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Neuroinflammation is considered to be a major factor in brain-aging—a decline in the structure and function of the brain with age. Presentation of childhood-onset…
Abstract Number: 062 • 2026 Pediatric Rheumatology Symposium
Evaluating the Relationship Between an Electronic Transition Planning Tool and Transition Success in a Pediatric Rheumatology Clinic
Karissa Chesky¹, Kyla Blasingame¹, Jimin Kim¹, Charles Lee², Alonzo Needum¹, Miriah Gillispie-Taylor³ and Tiphanie Vogel⁴, ¹Baylor College of Medicine, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ⁴Baylor College of Medicine/Texas Children's Hospital
Background/Purpose: Young adults with chronic health conditions deserve an intentional transition from pediatric to adult care. We have developed a longitudinal process to standardize transfer…
Abstract Number: 075 • 2026 Pediatric Rheumatology Symposium
Association of Anti-Cytokine Biologics and JAK inhibitors with Bronchoalveolar Fluid Cytokine Profiles in Patients with Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD)
Ivanna Romankevych¹, Donna Do¹, Alyssa Sproles¹, Lexi Auld¹, Taskin Sabit¹, Joy Baker¹, Richard Chhaing¹, John Brewington², Brenna Carey³, Bruce Trapnell³, Christopher Towe², Alexei Grom⁴ and Grant Schulert⁵, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, ²Cincinnati Children's Hospital Medical Center, Division of Pulmonology, ³Cincinnati Children's Hospital Medical Center, Division of Translational Pulmonary Science Center, ⁴Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Lung disease associated with systemic JIA (SJIA-LD) remains poorly understood. Compared to serum or plasma, measurement of cytokine levels in bronchoalveolar lavage fluid (BALF)…
Abstract Number: 085 • 2026 Pediatric Rheumatology Symposium
Outcomes of Oligoarticular Juvenile Idiopathic Arthritis Patients Treated with Intra-articular Glucocorticoids: Can We Predict Successful Treatment?
Andrew Kung¹, Kimberly Hays¹, Lisabeth Scalzi², Catherine Bingham³, Ferris Troy Yu Asensi⁴ and Timothy Hahn¹, ¹Penn State Childrens Hospital, Hershey, PA, ²Penn State Childrens Hospital, Hummelstown, PA, ³Penn State Childrens Hospital, ⁴Penn State Childrens Hospital, Jacksonville, FL
Background/Purpose: Intra-articular glucocorticoids (IAGCs) are a common first-line therapy for patients with oligoarticular juvenile arthritis. Limited data exist on rates and predictors of treatment escalation…
Abstract Number: 040 • 2026 Pediatric Rheumatology Symposium
Antiphospholipid Antibody-Mediated Disease: Clinical Characteristics and Outcomes of Catastrophic Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia in a Single Center Pediatric Cohort
Rasha Elrefai¹, Olivia Kwan², Jamie Lai³, Maria Pereira¹, Katie Stewart⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine; Texas Children's Hospital, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine
Background/Purpose: Catastrophic antiphospholipid syndrome (CAPS) and lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) represent distinct yet closely related antiphospholipid antibody-driven disease entities, caused by immune-mediated dysregulation of…
Abstract Number: 059 • 2026 Pediatric Rheumatology Symposium
Use of Multimodal Teaching to Improve Resident Confidence in Evaluating Rheumatic Conditions
Brittany Anderson¹, Kristina Ciaglia² and Simrat Morris³, ¹UT Southwestern, ²UT Southwestern, Dallas, TX, ³University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Pediatric rheumatology is underrepresented in residency core competencies, and many trainees report limited exposure to core rheumatic conditions.1 As a result, residents may feel insufficiently…
Abstract Number: 050 • 2026 Pediatric Rheumatology Symposium
The Quiet Beginning: Early Pediatric Systemic Lupus Erythematosus (SLE) Without Nephritis and the Path to Renal Involvement
Tara McGrath¹, Dax Rumsey¹, Lillian Lim¹ and Audrea Chen², ¹University of Alberta, Edmonton, AB, Canada, ²Stollery Children's Hospital, Edmonton, AB, Canada
Background/Purpose: It is well known that patients with juvenile Systemic Lupus Erythematosus (jSLE) are at much higher risk of developing Lupus Nephritis (LN) compared…
Abstract Number: 005 • 2026 Pediatric Rheumatology Symposium
Magnetic Resonance Enterography Detected Sacroiliitis in Pediatric Crohn’s Disease: A Retrospective Cohort Study
Aaisham Ali¹, Vishal Kalia², Ian Ross², Luke Daichendt³, Julia Sawicka⁴, Michael R Miller⁵, Sarah Wells⁶, Eileen Crowley⁶ and Roberta A Berard⁷, ¹Schulich School of Medicine & Dentistry, Pediatrics, London Health Sciences Centre, London, ON, Canada, ²Department of Medical Imaging, Western University, ³Schulich School of Medicine & Dentistry, Western University, ⁴Western University, ⁵Department of Pediatrics, Children's Hospital, London Health Sciences Centre, ⁶London Children's Hospital, ON, Canada, ⁷London Health Sciences Centre, London, ON, Canada
Background/Purpose: Musculoskeletal (MSK) manifestations are amongst the most common extraintestinal manifestations (EIMs) in pediatric Crohn’s disease (CD). MSK EIMs contribute to reduced quality of life…
Abstract Number: 012 • 2026 Pediatric Rheumatology Symposium
Prevalence and Impact of Adverse Childhood Experiences in Pediatric Systemic Lupus Erythematosus
Anita Dhanrajani¹, Rhea Bhargava² and Alfred Kim³, ¹Manning Family Children's Hospital, Tulane University, ²Tulane University Medicine, New Orleans, LA, ³Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Adverse childhood experiences (ACEs) have been linked to incident childhood-onset SLE (cSLE) and poorer patient-reported outcomes, raising the possibility that early-life stress may contribute…
Abstract Number: 090 • 2026 Pediatric Rheumatology Symposium
Characterizing CNS MRI Abnormalities in Pediatric ANCA-Associated Vasculitis
Dawn Gist¹, Eyal Muscal², Srikala Narayanan³ and Divya Thomas⁴, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, houston, TX, ³Texas Children's Hospital Division of Neuroradiology, ⁴Baylor College of Medicine/Texas Children's Hospital
Background/Purpose: CNS involvement in pediatric ANCA-associated vasculitis (AAV) is rare but can lead to significant neurological symptoms, including headaches, seizures, behavioral changes, and occasional cerebrovascular…
Abstract Number: 071 • 2026 Pediatric Rheumatology Symposium
The Association Between Age at Diagnosis and Health-Related Quality of Life in Takayasu Arteritis
Jessica Bloom¹, Kaci Pickett-Nairne², Lori Silveira², Cristina Burroughs³, Katrina Bargender⁴, Amy Bolton⁵, Christine Yeung⁶, Jennifer Gordon⁵, Peter A. Merkel⁷ and Karen James⁸, ¹University of Colorado Aurora, CO, ²University of Colorado, ³University of South Florida, ⁴Vasculitis Patient-Powered Research Network, Caledonia, WI, ⁵Vasculitis Patient-Powered Research Network, ⁶University of Pennsylvania, ⁷University of Pennsylvania, Philadelphia, United Kingdom, ⁸University of Utah, Salt Lake City, UT
Background/Purpose: Takayasu arteritis (TAK) can occur throughout the lifespan and impacts health-related quality of life (HRQoL). This study examined the relationship between age at diagnosis…
Abstract Number: 083 • 2026 Pediatric Rheumatology Symposium
Relative Risk of a Thrombotic Event in Janus Kinase Inhibitor Use for JIA using the Epic Cosmos Database
Alysha Taxter¹, Marissa Dale², Tova Ronis³, Nuria Lara Castillo⁴, Rajdeep Pooni⁵, Kelly Rouster-Stevens⁶, Caitlan Pinotti⁷ and CARRA Clinical Informatics Workgroup⁸, ¹Nationwide Children's, Columbus, OH, ²Hospital for Special Surgery/NYP Cornell, New York, NY, ³Children's National Hospital, George Washington University School of Medicine and Health Sciences, Chevy Chase, MD, ⁴University of Missouri - Kansas City, Kansas City, MO, ⁵Stanford University, Berkeley, CA, ⁶Emory University/Children's Healthcare of Atlanta, Peachtree Corners, GA, ⁷University of North Carolina, Cary, NC, ⁸Childhood Arthritis and Rheumatology Research Alliance, DC
Background/Purpose: An increased risk of thromboembolic events among patients taking a janus kinase inhibitor (JAKi) was seen in The Oral Rheumatoid Arthritis Trial Surveillance study.…
Abstract Number: 042 • 2026 Pediatric Rheumatology Symposium
Mindfulness Matters: Early Insights from the Making Mindfulness Matter© in children with Juvenile Idiopathic Arthritis Study.
Roberta A Berard¹, KAREN BEATTIE², Sarah Wells³, Michelle Batthish⁴, Asha Jeyanathan⁵, Frances Montemurro⁶, Karen Bax⁷ and Andrea Knight⁸, ¹London Health Sciences Centre, London, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³London Children's Hospital, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵Hospital for Sick Children, ON, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Adjunct Professor, Psychology, Western Ontario, ON, Canada, ⁸Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Poor mental health (MH) in the pediatric rheumatology population has been shown to affect quality of life, educational attainment, and disease-related outcomes, such as…

« Previous Page
1
…
4
5
6
7
8
…
2616
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].